CompletedPhase 2NCT02967679

SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

Studying Chronic inflammatory demyelinating polyneuropathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
MedDay Pharmaceuticals SA
Principal Investigator
Alain CREANGE, MD
Hôpital Henri Mondor, Créteil, France
Intervention
MD1003(drug)
Enrollment
15 enrolled
Eligibility
20-85 years · All sexes
Timeline
20162019

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02967679 on ClinicalTrials.gov

Other trials for Chronic inflammatory demyelinating polyneuropathy

Additional recruiting or active studies for the same condition.

See all trials for Chronic inflammatory demyelinating polyneuropathy

← Back to all trials